Ironwood Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparison is with Q1 2021. Ironwood is a gastrointestinal therapeutics company whose revenue is principally tied to LINZESS, marketed in the U.S. through its 50/50 collaboration with AbbVie. All financial amounts below are in U.S. dollars.
Key financial results
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $97.5 million | $88.8 million |
| Income from operations | $57.8 million | $45.4 million |
| Net income | $38.8 million | $39.9 million |
| Basic / diluted EPS | $0.25 / $0.21 | $0.25 / $0.25 |
| Operating cash flow | $64.1 million | $73.7 million |
- Revenue increased 9.8%; collaborative-arrangement revenue rose 10.0% to $97.5 million. Ironwood attributed most of the increase to higher U.S. LINZESS profits, driven by prescription demand growth and partly offset by net price erosion.
- Operating expenses declined 8.7% to $39.7 million. R&D fell 30% to $10.8 million, mainly due to lower IW-3718 development costs following its discontinuation and lower linaclotide costs. SG&A rose 4% to $28.9 million.
- Operating margin was approximately 59.3%, compared with 51.1% in Q1 2021; net margin was approximately 39.8%, compared with 44.9%.
- Net income declined 2.8% despite higher operating income, primarily reflecting income tax expense of $17.7 million versus $0.4 million a year earlier. The company said most of its tax provision is expected to be non-cash while available net operating losses are used.
- Interest expense decreased to $2.3 million from $7.6 million, mainly because adoption of ASU 2020-06 eliminated amortization of convertible-note discounts. Q1 2022 diluted EPS reflects the new if-converted accounting method and a higher diluted share count.
- Operating cash flow decreased 13.0% to $64.1 million. Share repurchases drove $90.9 million of financing cash outflow; cash, cash equivalents and restricted cash declined $26.8 million during the quarter.
Balance sheet, debt and capital allocation
- At March 31, 2022, cash and cash equivalents were $593.4 million; total cash, cash equivalents and restricted cash were $595.1 million. Accounts receivable totaled $119.7 million, including current and non-current balances.
- Total assets were $1.083 billion and stockholders’ equity was $517.8 million. The company reported $515.6 million of convertible notes on a net carrying-value basis; aggregate principal was $520.7 million, with $120.7 million of 2022 notes due within 12 months and maturing June 15, 2022.
- Management said cash on hand and expected operating cash inflows were sufficient for projected operating needs at least through the next 12 months. It expects to meet near- and long-term obligations, while noting forecasts could prove inaccurate.
- The company repurchased 8.0 million shares for $90.5 million in Q1 at an average $11.30 per share. $32.4 million remained under its $150 million authorization at quarter-end. From April 1–30, it repurchased a further 1.3 million shares for $15.9 million.
Business outlook, risks and notable items
- No specific revenue, earnings or cash-flow guidance was provided. Management expects LINZESS collaboration revenue to remain a significant portion of revenue and plans continued investment in linaclotide and GI pipeline programs.
- IW-3300 entered Phase I development for visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. COUR’s CNP-104 study for primary biliary cholangitis had a data readout estimated in 2023; Ironwood holds an option to license the program. The company had no clear estimate for the eventual timing or cost of development programs.
- COVID-19 had not significantly disrupted LINZESS manufacturing or supply as of the filing, but reduced in-person promotion, patient access, reimbursement changes and collaboration selling-cost fluctuations could affect future results.
- Key risks include dependence on LINZESS and the AbbVie relationship, net-price erosion, partner-reported sales and settlement calculations, clinical and regulatory uncertainty, competition, manufacturing and supply, intellectual-property litigation, and the ability to manage spending and debt obligations. The filing reported no material changes to previously disclosed risk factors.
- ASU 2020-06 adoption on January 1, 2022 changed convertible-debt accounting and increased reported debt while reducing future non-cash interest expense; the company estimated a $22.1 million decrease in 2022 non-cash interest expense versus 2021. Adoption did not affect liquidity or cash flows.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- LINZESS prescription trends, net pricing, and the components of Ironwood’s U.S. collaboration settlement with AbbVie.
- Repayment, conversion or other settlement of the $120.7 million 2022 notes due in June 2022, and the company’s remaining debt obligations.
- Cash generation relative to continued share repurchases, R&D spending and future obligations.
- Progress and data timing for IW-3300 and CNP-104, including any decision to exercise the CNP-104 license option.
- Actual tax expense and the use of net operating losses, as well as the effect of the accounting change on reported earnings and diluted EPS.